Maurice was discovered hunched over his Bloomberg terminal, methodically peeling a banana while muttering about the irony of life-saving medicines getting rejected by the very people they’re supposed to save money for.
Here’s a riddle for you: What’s the difference between a company that just won FDA accelerated approval for a groundbreaking gene therapy and a monkey who found a single banana in an otherwise empty barrel? One has the headline victory. The other understands what happens next.
That company is Rocket Pharmaceuticals (RCKT), and right now it’s having what I can only describe as the stock market equivalent of winning the lottery and immediately watching half your ticket blow away in the wind.
Let me back up and explain why I’m sitting here with banana peels scattered across my desk like confetti at a funeral.
In late March 2026, Rocket Pharmaceuticals achieved something genuinely remarkable: the FDA granted accelerated approval for KRESLADI, their gene therapy for severe Leukocyte Adhesion Deficiency Type I (LAD-I)—a rare immunodeficiency disorder in children that basically means the immune system can’t get out of bed to do its job. This is serious medicine for seriously desperate families. The kind of approval that should make investors dance.
So what did the market do? It punted. The stock dropped 8.9% on the news.
Now, before you think I’m about to tell you the market is stupid and you should sell everything, let me eat that banana peel first and actually think about what’s happening here.
The Approval Nobody Expected to Disappoint
Gene therapy approvals are still relatively rare. They’re the kind of regulatory milestone that used to send biotech stocks into orbit. But RCKT’s situation is more delicate than a banana split under a heat lamp, and the market’s reaction reveals something important about where we are in the biotech cycle right now.
Look at the numbers: RCKT is trading at $3.64, down from a 52-week high of $8.26. The company has a market cap of just under $400 million. The stock had been on a legitimate tear—up 59.7% over 20 days according to the recommendation brief—which means a lot of optimism was already baked in. Then came the approval. Then came the sell-off.
This happens more often than people realize in biotech. A company hits a milestone that validates years of research and hundreds of millions in burn, and the stock still drops. Why? Because the market is already three steps ahead, asking questions like: How many patients will actually get this treatment? How much will insurance companies pay? Will there be competition? And most importantly: when does this company actually start making money?
Rocket Pharmaceuticals is burning cash at a staggering rate—$104.8 million in negative free cash flow last period. They have a debt-to-equity ratio of 8.97, which is the financial equivalent of building a house on a foundation made of more debt. They have no revenue. No earnings. The profit margin is zero because there’s no profit.
One approval, even a beautiful one, doesn’t fix that equation overnight.
The Pipeline: Where the Real Monkey Lives
But here’s where I start throwing bananas at the pessimists’ heads: the approval is just the appetizer. The real meal is in the pipeline.
Rocket has two major platform technologies: in vivo AAV (adeno-associated viral) programs and ex vivo lentiviral programs. Think of these as two different tools for doing roughly the same thing—fixing broken genes—but in different ways and in different locations in the body.
The AAV programs include work on Danon disease (a multi-organ lysosomal disorder) in Phase 2, and a couple of earlier-stage cardiac programs. The lentiviral programs include two other ex vivo therapies for different genetic blood disorders. This isn’t a one-trick pony. This is a company with multiple shots on goal across multiple disease areas, all with limited competition because—let’s be honest—gene therapy is still the wild frontier of medicine.
KRESLADI getting approved proves the platform works. It proves the manufacturing process is scalable. It proves that regulatory pathways, while winding, do actually lead somewhere. Now the question becomes: how many of these other programs also work?
That’s the real value. And that’s why Wedbush recently called the company “significantly undervalued.” It’s not because KRESLADI itself is going to be a blockbuster. It’s because KRESLADI proves the entire architecture is sound.
The Valuation Puzzle (Which Makes My Head Hurt)
Let me do some actual math here, because the stock’s current price is weird in ways that matter.
Foxy’s recommendation came in at an entry price of $5.11 with a target of $9.50, implying 86% upside. The fresh data shows analyst consensus target price at $8.48. The stock is currently at $3.64. The 50-day average is $4.02. The 200-day average is $3.49.
Translation: we’re near recent lows, but we’re bouncing around in a relatively narrow band. This is what happens when a market doesn’t know how to value something. The smart money—institutional investors—are allegedly accumulating (per the note about “institutional accumulation”). But there’s also a short ratio of 4.64, which means short sellers have made this a battle zone.
The beta of 0.574 is genuinely interesting. A beta below 1.0 means this stock moves less dramatically than the broader market. That sounds boring until you realize what it actually means: the market has priced in the clinical-stage risk already. When the recommendation says the “clinical-stage risk is priced fairly,” it’s because the market has already decided this is a speculative play and priced accordingly. You’re not getting crushed on downside surprise because the expectations are already low.
That also means upside has more room to run.
The Reality Check
I need to be honest about what could go wrong here, because I’m a monkey, not a delusional monkey.
First: LAD-I is rare. “Rare” is the disease modifier that gets regulatory shortcuts (accelerated approval, orphan drug status) but also means the addressable market for KRESLADI might be measured in hundreds of patients, not thousands. Each patient might generate meaningful revenue, but we’re not talking blockbuster drug economics here. This is speciality pharma with a specialty market.
Second: The burn rate is real. Rocket needs cash or partnerships or both. Every percentage point of the pipeline that fails takes years off the runway. The company is currently trading near the low end of its range, which suggests the market is pricing in moderate-to-pessimistic assumptions about what comes next.
Third: Gene therapy as a category is still proving itself. Manufacturing is complex. Delivery is complex. Durability of effect is still being tested in real patients. One approval is validation. Multiple approvals would be vindication. But we’re not there yet.
Fourth: There’s competitive risk. Sesen Bio, Intellia Therapeutics, and other gene therapy shops are developing their own programs in similar disease areas. The fact that LAD-I has limited competition right now doesn’t mean it will forever.
What I’m saying is: this isn’t a free banana. It’s a free banana with strings attached, and some of those strings could get tangled.
Why I’m Still Intrigued
But here’s why I’m not dismissing this, and why Foxy’s recommendation has merit despite the market’s reaction:
Gene therapy is moving from “science project” to “actual medicine.” KRESLADI approval is evidence number one. Evidence number two is that the FDA is clearly willing to move quickly on therapies that solve urgent problems in small populations. Evidence number three is that Rocket has more programs than just KRESLADI.
The valuation multiple the market is applying right now is pessimistic. It’s pricing in scenarios where most of the pipeline fails. If even two or three of the early-stage programs show good Phase 2 data, the stock re-rates substantially. That’s not fantasy. That’s standard biotech valuation math.
The institutional accumulation Foxy noted is interesting. Smart money doesn’t usually accumulate in stocks they think are going to zero. They accumulate in stocks they think are pricing in too much pessimism. The short ratio of 4.64 means there’s genuine disagreement about direction, which creates volatility, which creates opportunity.
And here’s the thing about a 0.574 beta: when this stock finally moves decisively in one direction, it might move with less drama than you’d expect for a biotech, but it will move. The runway for multiple expansion is real.
The Three to Five Year Question
If I’m thinking like someone who has an actual portfolio and actual stakes in outcomes, here’s what I want to know: where is Rocket Pharmaceuticals in 2029 or 2030?
Best case: Two or three programs hit Phase 2 success. Partnerships form. Manufacturing ramps. The company stops burning money and starts making money. The clinical-stage risk premium compresses. The stock trades at a reasonable multiple to product sales. Target: $12-15 range.
Base case: KRESLADI generates modest revenue. One other program advances to Phase 3. The company stays cash-flow negative but the burn slows. Partners or investors step in. The stock drifts up to the $7-9 range over time, not in a straight line.
Worst case: Additional programs show disappointing data. Manufacturing or commercial challenges emerge. The company dilutes shareholders to raise cash. The stock stays depressed or goes lower. In this scenario, Rocket becomes an acquisition target or a cautionary tale.
Which scenario am I betting on? That’s the $3.64 question, isn’t it?
I’ll tell you what my banana pile suggests: the market is currently pricing in something closer to worst case than base case. The FDA approval actually argues for base case or better. The institutional accumulation suggests someone smart thinks it’s at least base case. The stock’s position near 52-week lows after hitting $8.26 suggests panic selling rather than rational repricing.
That’s typically when monkeys get interested.
The Uncomfortable Truth
The market’s muted reaction to KRESLADI approval isn’t dumb. It’s actually sophisticated in its own way. The market is saying: “Yes, you proved the science works. Now prove you can build a business around it.” That’s a fair ask. KRESLADI alone doesn’t prove that. But it opens the door.
If you’re looking for a stock that’s going to spike 50% on news tomorrow, this isn’t it. The news already came and the market yawned. What you’re actually looking at is a company with proven science, a pipeline with multiple shots on goal, a valuation that doesn’t assume much success, and a low beta that means when it finally moves, it might move without the volatility scare you’d expect.
That’s the kind of setup that rewards patience and conviction more than it rewards momentum chasing.
Foxy’s target of $9.50 (86% upside from current levels) feels reasonable if 2-3 year data reads go decently and partnerships materialize. The entry point at $5.11 was generous. The current price of $3.64 is actually better. This is exactly the kind of situation where you have to ask: “Am I scared because the stock is bad, or because it’s scary?” Biotech IS scary. Gene therapy IS early stage. But scary isn’t the same as bad.
The question for you is whether you have the stomach for a 3-5 year conviction play that might go sideways for 18 months before it goes somewhere. Some investors do. Some don’t. There’s no wrong answer—just different risk tolerances.
My tail is twitching though, and that usually means something interesting is happening.
Disclaimer: Trained Market Money, Maurice, and our entire primate analysis team provide entertaining market commentary only. While Maurice’s Monkey Momentum Index™ and banana-based technical analysis have shown mysterious accuracy, they should never be considered financial advice. All investment decisions should be made in consultation with qualified financial professionals, not monkeys – no matter how impressive their fruit-throwing abilities may be. For real financial advice, please consult your financial advisor, who probably doesn’t accept bananas as payment.
Coming next week: Why one semiconductor company is acting like it has a monopoly on bananas, and why the market hasn’t figured it out yet. Spoiler: there’s always a monkey who saw it first.
Maurice’s Final Word: “The best investments aren’t the ones that spike on good news. They’re the ones that spike on the day the market finally realizes the good news was already good.”
Trained Market Monkey 